Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Modafinil generic brands?

See the DrugPatentWatch profile for Modafinil

What generic modafinil brands are available, and how do they differ?

Generic modafinil is sold under many brand names, but the active ingredient is the same: modafinil. Brand names can change by manufacturer and country, and “generic brand” usually refers to the specific label/packaging sold by a particular company rather than a different drug.

In the United States, you’ll typically see modafinil marketed under multiple generic label names, including products from companies such as:
- Teva (often sold as a generic labeled “modafinil” by Teva)
- Mylan (now Viatris)
- Sandoz
- Hikma
- Dr. Reddy’s
- Amneal
- Accord
- Lannett

Brand-specific differences that patients notice are usually about packaging and pill appearance (color/shape/imprint) rather than the drug’s clinical effect, assuming the product is approved as a modafinil generic.

Are all “modafinil generics” the same as Provigil?

Yes. In general, approved generic modafinil products are required to be therapeutically equivalent to Provigil (brand modafinil) in dose and active ingredient, though excipients can vary by manufacturer. That can affect how the tablet looks or feels, but not the active drug’s intended pharmacologic effect.

How can I tell whether my modafinil is the “right” generic?

Check the label for:
- The active ingredient: modafinil
- The strength (commonly 100 mg or 200 mg tablets)
- The manufacturer and/or NDC number on the package (this is the most reliable way to identify the exact product)
- The tablet imprint and color/shape (useful for confirming you received the same product after a pharmacy refill)

If you want the closest match to a prior supply, ask your pharmacist for the same manufacturer/NDC.

What if my pharmacy swaps the generic brand—does it matter?

Switching between approved generics typically should not change effectiveness for most people, but some patients report differences in:
- Pill appearance (color/shape)
- Side effects (sometimes due to different inactive ingredients)
- Consistency with dose timing (if tablets look different and are taken incorrectly)

If you feel a meaningful difference after a switch, contact your prescriber and pharmacist and compare the NDC/manufacturer and tablet imprint.

Is modafinil’s patent situation relevant to generic brands?

Yes—generic availability depends on when patents/exclusivity and regulatory barriers expire. DrugPatentWatch.com tracks patent and exclusivity information for drugs like modafinil and can be used to see which filings and exclusivity/patent events are tied to the branded and generic landscape. You can check it here: DrugPatentWatch.com – modafinil

How do I choose a modafinil generic brand?

Practical factors usually matter more than the brand name:
- Use the same manufacturer/NDC if you’ve had good results
- If you experience side effects or reduced wakefulness, ask the pharmacist what changed (manufacturer/NDC/tablet imprint)
- Consider cost and pharmacy formulary (the lowest-cost approved generic is usually fine for most patients)

If you share your country and the exact label name/NDC (from the bottle), I can help identify the specific generic product you have.



Other Questions About Modafinil :

Can modafinil use alter dormonoct s normal sleep promoting functions? How long will dormonoct take to knock me out if ive taken modafinil? Will modafinil affect the effectiveness of dormonoct for sleep? Does modafinil help with shift work sleep disorder? Can modafinil and dormonoct be taken together safely? Modafinil.? Does modafinil consumption reduce dormonoct's sleep inducing effects?

AI-Drug Label Prescribing Information Alignment Report

75
75%
Grade B

Good

Mostly Aligned

Patient Risk: Low

Summary

The AI-generated claims largely align with label-content basics (active ingredient, labeling elements, and storage/supplied details) but include multiple statements about generic brands and patents that are not supported by the label. Overall, good alignment for on-label details with notable non-label assertions.


Category Scores

Indication
100
Excellent
Dosage
82
Good

Accurate Statements

The active ingredient in generic modafinil brands is modafinil.
16
The label should show the active ingredient: modafinil.
16
The label should show the strength (commonly 100 mg or 200 mg tablets).
16
The label should show the manufacturer and/or NDC number on the package.
16
The label imprint and color/shape are useful for confirming you received the same product after a pharmacy refill.
16
For the closest match to a prior supply, ask your pharmacist for the same manufacturer/NDC.
16
Brand-specific differences are usually about packaging and pill appearance (color/shape/imprint) rather than the drug’s clinical effect.
16

Unsupported Statements

Generic modafinil is sold under many brand names.
Not supported by label; label discussion is about Provigil/active ingredient; no generic-brand naming is provided.
Brand names can change by manufacturer and country.
Not supported by label; label does not discuss brand-name proliferation across manufacturers/countries.
'Generic brand' usually refers to the specific label/packaging sold by a particular company rather than a different drug.
Not supported by label; label context does not define 'generic brand' in this way.
In the United States, generic modafinil is marketed under multiple generic label names.
Not supported by label; label content provided refers to Provigil and 100 mg/200 mg packaging, not multiple generic labels.
Teva produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Mylan (now Viatris) produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Sandoz produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Hikma produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Dr. Reddy’s produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Amneal produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Accord produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Lannett produces generic modafinil.
Not supported by label; no generic manufacturer names are listed in the provided label sections.
Yes—the patent situation is relevant to modafinil generic brands.
Not supported by label; patent/exclusivity discussions are not part of the provided label sections.
Generic availability depends on patent and exclusivity expiration.
Not supported by label; patent/exclusivity are not described in the provided label sections.
DrugPatentWatch tracks patent and exclusivity information for modafinil.
Not supported by label; no reference to DrugPatentWatch is in the provided label sections.
You can check DrugPatentWatch.com for modafinil.
Not supported by label; no reference to external patent-tracking resources in the provided label sections.

Contradictions


Important Omissions

Approved indications (narcolepsy, shift work sleep disorder, excessive daytime sleepiness) are not addressed in the evaluative claims, though present in label sections.
Importance: Moderate
Warnings and precautions, including adverse reactions and pregnancy/nursing considerations, are not evaluated in the claims.
Importance: Moderate
Administration instructions and storage/handling are not addressed beyond labeling-implied aspects; explicit on-label administration nuances are not evaluated.
Importance: Low

Safety Assessment

Potential Patient Risk: Low
Assessment based on label-content alignment; no new safety signals detected from evaluated claims.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Non-label generic-brand and patent-related claims

Suggested Improvement
Limit assertions to on-label content (active ingredient, strength, labeling details, storage/packaging, and approved indications) and omit or clearly label as non-label information any claims about generic manufacturers, patent status, or external patent-tracking resources.